EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Drug Patent Profile

When do Empagliflozin And Metformin Hydrochloride patents expire, and when can generic versions of Empagliflozin And Metformin Hydrochloride launch?

Empagliflozin And Metformin Hydrochloride is a drug marketed by Zydus Pharms and is included in one NDA.

The generic ingredient in EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Summary for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	69
Patent Applications:	4
DailyMed Link:	EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novo Nordisk A/S	Phase 3
SINA Health Education and Welfare Trust	Phase 2/Phase 3
SINA Health Education and Welfare Trust	Phase 4

See all EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE clinical trials

US Patents and Regulatory Information for EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	empagliflozin; metformin hydrochloride	TABLET;ORAL	212198-002	Jul 7, 2022		DISCN	No	No
Zydus Pharms	EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	empagliflozin; metformin hydrochloride	TABLET;ORAL	212198-003	Jul 7, 2022		DISCN	No	No
Zydus Pharms	EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	empagliflozin; metformin hydrochloride	TABLET;ORAL	212198-001	Jul 7, 2022		DISCN	No	No
Zydus Pharms	EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE	empagliflozin; metformin hydrochloride	TABLET;ORAL	212198-004	Jul 7, 2022		DISCN	No	No